Cargando…

Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer

Type 2 diabetes mellitus (T2DM) has consistently been associated with decreased risk of prostate cancer; however, if this decrease is related to the use of anti‐diabetic drugs is unknown. We prospectively studied men in the comparison cohort in the Prostate Cancer data Base Sweden 3.0, with data on...

Descripción completa

Detalles Bibliográficos
Autores principales: Häggström, Christel, Van Hemelrijck, Mieke, Zethelius, Björn, Robinson, David, Grundmark, Birgitta, Holmberg, Lars, Gudbjörnsdottir, Soffia, Garmo, Hans, Stattin, Pär
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215657/
https://www.ncbi.nlm.nih.gov/pubmed/27770555
http://dx.doi.org/10.1002/ijc.30480
_version_ 1782491796995047424
author Häggström, Christel
Van Hemelrijck, Mieke
Zethelius, Björn
Robinson, David
Grundmark, Birgitta
Holmberg, Lars
Gudbjörnsdottir, Soffia
Garmo, Hans
Stattin, Pär
author_facet Häggström, Christel
Van Hemelrijck, Mieke
Zethelius, Björn
Robinson, David
Grundmark, Birgitta
Holmberg, Lars
Gudbjörnsdottir, Soffia
Garmo, Hans
Stattin, Pär
author_sort Häggström, Christel
collection PubMed
description Type 2 diabetes mellitus (T2DM) has consistently been associated with decreased risk of prostate cancer; however, if this decrease is related to the use of anti‐diabetic drugs is unknown. We prospectively studied men in the comparison cohort in the Prostate Cancer data Base Sweden 3.0, with data on T2DM, use of metformin, sulfonylurea and insulin retrieved from national health care registers and demographic databases. Cox proportional hazards regression models were used to compute hazard ratios (HR) and 95% confidence intervals (CI) of prostate cancer, adjusted for confounders. The study consisted of 612,846 men, mean age 72 years (standard deviation; SD = 9 years), out of whom 25,882 men were diagnosed with prostate cancer during follow up, mean time of 5 years (SD = 3 years). Men with more than 1 year's duration of T2DM had a decreased risk of prostate cancer compared to men without T2DM (HR = 0.85, 95% CI = 0.82–0.88) but among men with T2DM, those on metformin had no decrease (HR = 0.96, 95% CI = 0.77–1.19), whereas men on insulin (89%) or sulfonylurea (11%) had a decreased risk (HR = 0.73, 95% CI = 0.55–0.98), compared to men with T2DM not on anti‐diabetic drugs. Men with less than 1 year's duration of T2DM had no decrease in prostate cancer risk (HR = 1.11, 95% CI = 0.95–1.31). Our results gave no support to the hypothesis that metformin protects against prostate cancer as recently proposed. However, our data gave some support to an inverse association between T2DM severity and prostate cancer risk.
format Online
Article
Text
id pubmed-5215657
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52156572017-01-18 Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer Häggström, Christel Van Hemelrijck, Mieke Zethelius, Björn Robinson, David Grundmark, Birgitta Holmberg, Lars Gudbjörnsdottir, Soffia Garmo, Hans Stattin, Pär Int J Cancer Cancer Epidemiolog Type 2 diabetes mellitus (T2DM) has consistently been associated with decreased risk of prostate cancer; however, if this decrease is related to the use of anti‐diabetic drugs is unknown. We prospectively studied men in the comparison cohort in the Prostate Cancer data Base Sweden 3.0, with data on T2DM, use of metformin, sulfonylurea and insulin retrieved from national health care registers and demographic databases. Cox proportional hazards regression models were used to compute hazard ratios (HR) and 95% confidence intervals (CI) of prostate cancer, adjusted for confounders. The study consisted of 612,846 men, mean age 72 years (standard deviation; SD = 9 years), out of whom 25,882 men were diagnosed with prostate cancer during follow up, mean time of 5 years (SD = 3 years). Men with more than 1 year's duration of T2DM had a decreased risk of prostate cancer compared to men without T2DM (HR = 0.85, 95% CI = 0.82–0.88) but among men with T2DM, those on metformin had no decrease (HR = 0.96, 95% CI = 0.77–1.19), whereas men on insulin (89%) or sulfonylurea (11%) had a decreased risk (HR = 0.73, 95% CI = 0.55–0.98), compared to men with T2DM not on anti‐diabetic drugs. Men with less than 1 year's duration of T2DM had no decrease in prostate cancer risk (HR = 1.11, 95% CI = 0.95–1.31). Our results gave no support to the hypothesis that metformin protects against prostate cancer as recently proposed. However, our data gave some support to an inverse association between T2DM severity and prostate cancer risk. John Wiley and Sons Inc. 2016-11-03 2017-02-01 /pmc/articles/PMC5215657/ /pubmed/27770555 http://dx.doi.org/10.1002/ijc.30480 Text en © 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Epidemiolog
Häggström, Christel
Van Hemelrijck, Mieke
Zethelius, Björn
Robinson, David
Grundmark, Birgitta
Holmberg, Lars
Gudbjörnsdottir, Soffia
Garmo, Hans
Stattin, Pär
Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
title Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
title_full Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
title_fullStr Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
title_full_unstemmed Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
title_short Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
title_sort prospective study of type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
topic Cancer Epidemiolog
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215657/
https://www.ncbi.nlm.nih.gov/pubmed/27770555
http://dx.doi.org/10.1002/ijc.30480
work_keys_str_mv AT haggstromchristel prospectivestudyoftype2diabetesmellitusantidiabeticdrugsandriskofprostatecancer
AT vanhemelrijckmieke prospectivestudyoftype2diabetesmellitusantidiabeticdrugsandriskofprostatecancer
AT zetheliusbjorn prospectivestudyoftype2diabetesmellitusantidiabeticdrugsandriskofprostatecancer
AT robinsondavid prospectivestudyoftype2diabetesmellitusantidiabeticdrugsandriskofprostatecancer
AT grundmarkbirgitta prospectivestudyoftype2diabetesmellitusantidiabeticdrugsandriskofprostatecancer
AT holmberglars prospectivestudyoftype2diabetesmellitusantidiabeticdrugsandriskofprostatecancer
AT gudbjornsdottirsoffia prospectivestudyoftype2diabetesmellitusantidiabeticdrugsandriskofprostatecancer
AT garmohans prospectivestudyoftype2diabetesmellitusantidiabeticdrugsandriskofprostatecancer
AT stattinpar prospectivestudyoftype2diabetesmellitusantidiabeticdrugsandriskofprostatecancer